Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder

A technology for the treatment of motor dysfunction and drugs, which is applied in the field of drugs for the treatment of traumatic neurological disorders and/or motor dysfunction, and can solve problems such as unclear effects

Inactive Publication Date: 2009-02-18
GLYCOSCIENCE LAB INC
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of IL-12 in spinal cord injury is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder
  • Therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder
  • Therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0072] Embodiments of the present invention will be explained below with reference to the drawings. However, the present invention is not limited to the Examples set forth below.

[0073] [Materials and methods]

[0074] [Preparation of L4]

[0075] Using the method of Xu et al., as described below, L4 was prepared by degradation of keratan sulfate with cutinase II followed by separation by anion exchange chromatography.

[0076] KS oligosaccharide (L4) was isolated from the degradation product of cutanase II from shark fin keratan sulfate (Biochemical Industry) by performing a series of steps of anion exchange chromatography and gel permeation chromatography. The oligosaccharide was identified by capillary electrophoresis and mass spectrometry (Non-Patent Document 4).

[0077] Capillary electrophoresis was performed using a Quanta 4000 capillary electrophoresis system (Waters) with UV detector. In capillary electrophoresis systems, the sample is loaded on the anode, using...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a therapeutic agent for traumatic neuropathy and / or movement disorder, particularly a therapeutic agent for traumatic neuropathy and / or movement disorder caused by spinal cord injury. It is found that a keratan sulfate oligosaccharide or a derivative thereof has an ameliorative effect on traumatic neuropathy and / or movement disorder caused by spinal cord injury and therefore is useful as a therapeutic agent for traumatic neuropathy and / or movement disorder. Thus, provided is a therapeutic agent for traumatic neuropathy and / or movement disorder, wherein the therapeutic agent comprises an effective amount of a keratan sulfate oligosaccharide or a derivative thereof.

Description

technical field [0001] The present invention relates to a therapeutic drug for traumatic nerve disorder and / or motor dysfunction, in particular to a therapeutic drug for traumatic nerve disorder and / or motor dysfunction caused by spinal cord injury. Background technique [0002] It is reported that Asari et al. have found that L4, keratan sulfate disaccharide shown in the following formula, has an inhibitory effect on the expression of interleukin-12 (IL-12) (Non-Patent Document 1). [0003] Gal(6S)β1-4GlcNAc(6S) [0004] (wherein, Gal represents a galactose residue, GlcNAc represents an N-acetylglucosamine residue, 6S ​​represents that the hydroxyl group at the 6-position is in the form of a 6-O-sulfate ester, and β1-4 represents a β1-4 glycosidic bond.) [0005] IL-12 is known to express at a high level in MRL-1pr / 1pr mice, immortalize T lymphocytes (CD4-CD8-), and swell lymphoid organs (lymph nodes and spleen) (Non-Patent Document 2). In addition, it has been reported t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/737A61P25/00C07H11/00C08B37/00
CPCA61K31/737A61P25/00
Inventor 浅利晃加藤忠彦
Owner GLYCOSCIENCE LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com